2022年のおもな業績

総説

  1. 奥山結香，綱島亮，直居靖人．多遺伝子アッセイの現状と問題点．腫瘍内科30巻2号 Page211-215．
  2. 松井智也，綱島亮，直居靖人．【多遺伝子発現解析の臨床応用】多遺伝子アッセイCurebest 95GC Breastの開発と臨床応用．癌の臨床37巻5号 Page385-394．
  3. 綱島亮，直居靖人．【多遺伝子発現解析の臨床応用】多遺伝子発現解析の今後の展望．乳癌の臨床37巻5号 Page395-405．
  4. 直居靖人，綱島亮，加藤千翔．乳癌における多遺伝子診断法の開発と臨床応用．京都府立医科大学雑誌131巻11号 Page891-900．

原著

  1. Morita M, Shimomura A, Tokuda E, Horimoto Y, Kawamura Y, Ishizuka Y, Sekine K, Obayashi S, Kojima Y, Uemura Y, Higuchi T. “Is adjuvant chemotherapy necessary in older patients with breast cancer?” Breast Cancer. 2022; 29(3):498-506.
  2. Abe K, Shimoda M, Yoshinami T, Sota Y, Miyake T, Tanei T, Kagara N, Naoi Y, Shimazu K. A case of sternal osteomyelitis during treatment with everolimus for recurrent breast cancer. Surg Case Rep. 2022 Jan 28;8(1):23.
  3. Kubo A, Tanei T, R Pradipta A, Morimoto K, Fujii M, Sota Y, Miyake T, Kagara N, Shimoda M, Naoi Y, Motoyama Y, Morii E, Tanaka K, Shimazu K. Comparison of "click-to-sense" assay with frozen section analysis using simulated surgical margins in breast cancer patients. Eur J Surg Oncol. 2022 Jul;48(7):1520-1526.
  4. Shiraishi M, Sowa Y, Kodama T, Numajiri T, Taguchi T, Amaya F. Localization of Chronic Pain in Postmastectomy Patients: A Prospective Comparison Between Patients With and Without Breast Reconstruction. Ann Plast Surg. 2022 May 1;88(5):490-495.
  5. Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRNA001: E-SPEC study. Breast Cancer. 2022 Sep;29(5):796-807.
  6. Kanbayashi Y, Sakaguchi K, Ishikawa T, Tabuchi Y, Takagi R, Yokota I, Katoh N, Takayama K, Taguchi T. Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial. Med Oncol. 2022 Jul 19;39(10):153.
  7. Yamada K, Kaise H, Taguchi T, Horiguchi J, Takao S, Suzuki M, Kubota T, Miura D, Narui K, Tawaraya K, Machida Y, Akazawa K, Kohno N, Ishikawa T; JONIE Study Group. Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer. J Bone Miner Metab. 2022 Nov;40(6):998-1006. 

国内学会（シンポジウムなど）

  1. 直居靖人．シンポジウム　遺伝子発現プロファイルを用いた各種多遺伝子アッセイの開発と臨床応用，第30回日本乳癌学会総会，2022，横浜．
  2. 阪口晃一．ランチョンセミナー　術後ホルモン療法のQOLと副作用対策．第10回日本乳房オンコプラスティックサージャリー学会総会，2022，沖縄．
  3. 阪口晃一．スポンサードセミナー　術後ホルモン療法のストラテジーとQOL．第19回日本乳癌学会東北地方会，2022，福島．